Imaging Acetadote Metabolism in Glioblastoma

This study is looking at how a drug called Acetadote affects glioblastoma (a type of brain cancer) in newly diagnosed patients. Researchers believe Acetadote, which helps reduce cell damage (oxidative stress), might change how brain tumors grow. You might be able to join if you are at least 18 years old, have newly diagnosed glioblastoma, and meet certain health requirements. The main goal is to see how Acetadote changes glioblastoma using special MRI scans and by looking at tumor tissue. The study plans to enroll 10 participants, and its current status is unclear.

Study design: This is an interventional study with a planned enrollment of 10 participants.
What's involved: Participants will receive Acetadote intravenously over 1 hour. The effect of Acetadote on glioblastoma metabolism will be measured at Day 1 and up to 21 days from Day 1.
Compensation: Not stated in the trial record.
Follow-up: Metabolism changes will be measured up to 21 days from Day 1.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Imaging Acetadote Metabolism in Glioblastoma

Recruiting

EARLY_PHASE1Ages 18+InterventionalTreatment

University of Texas Southwestern Medical Center

~10 participants

Updated 2026-06-23 on ClinicalTrials.gov

What's tested:Acetadote

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

To determine the effect of Acetadote on glioblastoma metabolism as measured by MRS.

Measured over Day 1 and up to 21 days from Day 1

Conditions

Glioblastoma

GBM

Where it's being run

1 sites across 1 states

Texas1

Who to contact

Omar Raslan, MBBCH, MPH, CCRP

[email protected]

214-648-7097

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

1\. Glioblastoma

2\. Newly diagnosed with no prior surgery, radiation, chemotherapy, or other tumor-treating agent

3\. Age ≥18 years

4\. KPS \> 70

5\. Adequate organ and marrow function as defined below:

\- Bilirubin ≤1.5 times upper limit of normal

\- AST and ALT ≤ 3 times ULN

\- Creatinine ≤ 1.5 x ULN and/or GFR ≤ 60 mL/min

-ANC ≥ 1000 cells/ul

\- Platelet ≥ 100,000/ul

\- Hemoglobin ≥ 9 g/dl

6\. All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

6a. A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

\- Has not undergone a hysterectomy or bilateral oophorectomy; or

\- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

7\. Ability to understand and the willingness to sign a written informed consent.

Exclusion

1.Chemotherapy, radiotherapy, or other cancer therapy within 4 weeks prior to starting study treatment.

2\. Subjects must have recovered from prior treatment-related toxicities to grade 2 or baseline (excluding alopecia and clinically stable toxicities requiring ongoing medical management, such as hypothyroidism from prior immune checkpoint inhibitor treatment).

3\. Subjects may not be receiving any other investigational agents for the treatment of the cancer under study.

4\. Brain metastases

5\. History of allergic or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to Acetadote.

6\. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.

7\. Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.

What this trial measures

To determine the effect of Acetadote on glioblastoma metabolism as measured by MRS.Day 1 and up to 21 days from Day 1
The effect of Acetadote on glioblastoma metabolism will be assessed by measuring cysteine, glutathione, and lactate in glioblastoma through MRS.

Trialytics